Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Torcetrapib + atorvastatin (Pfizer).

John R Burnett1

  • 1Royal Perth Hospital, Department of Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine WA, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au

Current Opinion in Investigational Drugs (London, England : 2000)
|September 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management.

Expert opinion on emerging drugs·2026
Same author

<i>ANGPTL3</i> gene editing with CRISPR-Cas9: early trial insights.

Expert opinion on investigational drugs·2026
Same author

Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a).

Expert opinion on investigational drugs·2025
Same author

Assessing the clinical progress of muvalaplin for reducing lipoprotein(a).

Expert opinion on investigational drugs·2025
Same author

Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials.

Expert opinion on investigational drugs·2025
Same author

Incidental Finding of Severe Hypertriglyceridaemia and Diagnosis of Familial Chylomicronaemia Syndrome in a Family.

Journal of paediatrics and child health·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Pfizer is investigating a combination therapy for atherosclerosis and high cholesterol. This new tablet combines torcetrapib, a CETP inhibitor, with atorvastatin, an HMG-CoA reductase inhibitor, in ongoing Phase III trials.

Area of Science:

  • Cardiovascular Pharmacology
  • Drug Development
  • Lipid Metabolism

Background:

  • Atherosclerosis and hypercholesterolemia are significant cardiovascular risk factors.
  • Current treatments aim to manage lipid profiles and reduce cardiovascular events.
  • Novel therapeutic targets for lipid management are under investigation.

Purpose of the Study:

  • To evaluate a novel combination tablet for treating atherosclerosis and hypercholesterolemia.
  • To assess the efficacy and safety of torcetrapib combined with atorvastatin.
  • To explore the potential of cholesteryl ester transfer protein (CETP) inhibition in lipid management.

Main Methods:

  • Phase III clinical trials are being conducted.
  • The study involves a combination tablet containing torcetrapib and atorvastatin.

Related Experiment Videos

  • Participants will be assessed for therapeutic effects on lipid parameters and atherosclerosis progression.

    • Main Results:

    • Data from Phase III trials are pending.
    • The combination targets both high-density lipoprotein cholesterol enhancement and HMG-CoA reductase inhibition.
    • Pharmacodynamic and pharmacokinetic profiles of the combination are under evaluation.

    Conclusions:

    • The combination tablet represents a potential new therapeutic strategy for cardiovascular disease.
    • Further results from Phase III trials are necessary to confirm clinical utility.
    • This research may offer insights into the role of CETP inhibition in managing dyslipidemia.